Skip to main content
Article thumbnail
Location of Repository

The proteomics in prostate cancer biomarker discovery

By V. E. Shevchenko, A. V. Olenich and N. E. Olenich


<p>Prostate cancer (PC) represents the second most frequent type of tumor in men worldwide. Proteomics represents a promising approach for the discovery of new biomarkers able to improve the management of PC patients. Markers more specific and sensitive than prostate-specific antigen are needed for PC diagnosis, prognosis and response to treatment. Moreover, proteomics could represent an important tool to identify new molecular targets for PC tailored therapy. Now several possible PC biomarkers sources, each with advantages and limitations, are under investigation, including tissues, urine, serum, plasma and prostatic fluids. Innovative high-throughput proteomic platforms are now identifying and quantifying new specific and sensitive biomarkers for PC detection, stratification and treatment. Nevertheless, many putative biomarkers are still far from being applied in clinical practice.</p><p>This review aims to discuss the recent advances in PC proteomics, emphasizing biomarker discovery and their application to clinical utility for diagnosis and patient stratification.</p

Topics: prostate cancer, proteomics, biomarkers, mass spectrometry, tumor tissues, body fluids, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Publisher: ABV-press
Year: 2015
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.